Promising use of metformin in treating neurological disorders: biomarker-guided therapies.
Promising use of metformin in treating neurological disorders: biomarker-guided therapies.
复制标题
二甲双胍在神经疾病治疗中的前景：生物标记物引导疗法。
DOI：
10.4103/1673-5374.385286
复制
发表时间：
2024-05
影响因子：
6.1
通讯作者：
Wang J
中科院分区：
文献类型：
--
作者：
Loan A;Syal C;Lui M;He L;Wang J
神经障碍是影响神经系统的一组不同的病症，包括神经退行性疾病（阿尔茨海默病、多发性硬化症、帕金森病、亨廷顿病）、脑血管病症（中风）和神经发育障碍（自闭症谱系障碍）。虽然它们影响着世界各地数百万人，但目前只有有限的有效治疗方案。由于大多数神经系统疾病表达与糖尿病相关的代谢紊乱，二甲双胍，一种双胍II型抗糖尿病药物，已经吸引了很多关注，通过纠正其紊乱的能量代谢来重新用于治疗神经系统疾病。然而，关于二甲双胍对这些神经系统疾病的有益/有害作用的研究存在争议。鉴于大多数神经系统疾病在其病理生理学中具有复杂的病因学，并且受到各种风险因素（如衰老、生活方式、遗传学和环境）的影响，因此确定二甲双胍在这些神经系统疾病中可以靶向的干扰分子功能非常重要。然后，这些分子可以用作生物标志物，对显示出不同分子/病理学特性并对二甲双胍治疗有反应的患者亚群进行分层，最终开发靶向治疗。在这篇综述中，我们将讨论这些神经系统疾病中与二甲双胍相关的代谢紊乱和受损的分子通路，以及如何将这些作为生物标志物来指导二甲双胍反应性治疗，用于治疗神经系统疾病的靶向治疗。
Neurological disorders are a diverse group of conditions that affect the nervous system and include neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, Huntington’s disease), cerebrovascular conditions (stroke), and neurodevelopmental disorders (autism spectrum disorder). Although they affect millions of individuals around the world, only a limited number of effective treatment options are available today. Since most neurological disorders express mitochondria-related metabolic perturbations, metformin, a biguanide type II antidiabetic drug, has attracted a lot of attention to be repurposed to treat neurological disorders by correcting their perturbed energy metabolism. However, controversial research emerges regarding the beneficial/detrimental effects of metformin on these neurological disorders. Given that most neurological disorders have complex etiology in their pathophysiology and are influenced by various risk factors such as aging, lifestyle, genetics, and environment, it is important to identify perturbed molecular functions that can be targeted by metformin in these neurological disorders. These molecules can then be used as biomarkers to stratify subpopulations of patients who show distinct molecular/pathological properties and can respond to metformin treatment, ultimately developing targeted therapy. In this review, we will discuss mitochondria-related metabolic perturbations and impaired molecular pathways in these neurological disorders and how these can be used as biomarkers to guide metformin-responsive treatment for the targeted therapy to treat neurological disorders.
登录
查看更多内容
影响因子：
82.9
作者：
Ayoub R;Ruddy RM;Cox E;Oyefiade A;Derkach D;Laughlin S;Ades-Aron B;Shirzadi Z;Fieremans E;MacIntosh BJ;de Medeiros CB;Skocic J;Bouffet E;Miller FD;Morshead CM;Mabbott DJ
通讯作者：
Mabbott DJ
影响因子：
5.6
作者：
Zhang, Gufang;Chen, Shuangshuang;Jia, Jia;Liu, Chun;Wang, Weipeng;Zhang, Hongjian;Zhen, Xuechu
通讯作者：
Zhen, Xuechu
影响因子：
7.1
作者：
Arawaka S;Sato H;Sasaki A;Koyama S;Kato T
通讯作者：
Kato T
影响因子：
5.6
作者：
Jankeviciute S;Svirskiene N;Svirskis G;Borutaite V
通讯作者：
Borutaite V
影响因子：
7.5
作者：
Arabmoazzen, Saiedeh;Mirshekar, Mohammad Ali
通讯作者：
Mirshekar, Mohammad Ali